Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 687 of 5804
-
New immune duo shows promise in preventing Post-Transplant infection
Prevention CompletedCMV infection in transplantation remains the most frequent infectious complication causing increased morbidity and mortality. International recommendations advocate prevention of this infection by instituting direct antiviral treatment or monitoring viral replication by PCR with …
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Prevention
Last updated Jun 27, 2026 12:32 UTC
-
New shot could help prevent bleeding in severe hemophilia
Disease control Recruiting nowStudy B7841007 is an open-label extension study to assess the long-term safety, tolerability, and efficacy of prophylaxis treatment with marstacimab in participants who did not require "Early Termination" from the Phase 3 Study B7841005 and from the Phase 3 Study B7841008. Study…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for kids with rare kidney disease: crovalimab trial underway
Disease control OngoingThis study aims to evaluate the efficacy and safety of crovalimab in pediatric participants with aHUS.
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Hope for rare brain disease: new drug aims to slow MSA
Disease control OngoingTo find out the effect of Lu AF82422 on disease progression in participants with multiple system atrophy.
Phase: PHASE2 • Sponsor: H. Lundbeck A/S • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug zanidatamab aims to shrink early breast cancer tumors before surgery
Disease control Recruiting nowThis is a Phase 2, single-site, single-arm open-label trial of zanidatamab in patients with early stage, low risk HER2+ BC. The primary objective is to determine the efficacy of zanidatamab for patients with early stage HER2/neu positive (HER2+) breast cancer (BC) as determined …
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug cocktail aims to fight advanced lung cancer
Disease control CompletedThis study aimed to evaluate the safety and effectiveness of ociperlimab combined with tislelizumab and chemotherapy, compared to tislelizumab and chemotherapy alone, in participants with non-small cell lung cancer (NSCLC) that was locally advanced, could not be removed by surger…
Phase: PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 26, 2026 18:31 UTC
-
New COVID booster shows promise in Mix-and-Match trial
⭐️ VACCINE ⭐️ CompletedThis Phase IIb clinical study aims to compare the immunogenicity and safety of a booster dose of recombinant protein RBD fusion dimer vaccine as a heterologous booster (to subjects who have received the second dose of the Pfizer-BioNTech (Comirnaty) COVID-19 vaccine at least 182 …
Phase: PHASE2 • Sponsor: Hipra Scientific, S.L.U • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 11:01 UTC
-
Tiny doses, big hope: new therapy may help kids outgrow nut allergies
Disease control CompletedThe LMNOP trial will be a 2-armed, open-label, randomised controlled trial (RCT), 2:1. Over a period of 18 months, children in the Multi-Nut Oral Immunotherapy Treatment (OIT) Group (experimental arm) will undergo low dose OIT to two nuts they are allergic to. At this time, child…
Phase: NA • Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New heart valve device tested in humans for first time
Disease control OngoingA prospective, non-randomized, single-arm, single-center, first-in-human study designed to evaluate the safety and feasibility of the DurAVR™ THV System in the treatment of subjects with symptomatic severe aortic stenosis.
Phase: NA • Sponsor: Anteris Technologies Ltd. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for kids with leukemia in Low-Income countries
Disease control Recruiting nowThe LALGFA2019 Recommendations redefine the standard risk criteria and propose to introduce anthracycline induction in so-called high-risk forms (LAL line T and LAL line B with leukocytosis greater than or equal to 50 G/L or in children less than 1 year of age or more than 10 yea…
Sponsor: French Africa Pediatric Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
One pill to treat heart failure? new study tests simpler approach
Disease control CompletedHeart failure with a reduced ejection fraction (HFrEF) represents a significant public health burden in the United States, with a growing prevalence particularly among African Americans and Hispanic Americans and individuals of low socioeconomic status (SES). Although effective t…
Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New drug cocktail offers hope for kids with relapsed leukemia
Disease control OngoingThe purpose of this study is to test the safety and determine the best dose of venetoclax and selinexor when given with chemotherapy drugs in treating pediatric and young adult patients with acute myeloid leukemia (AML) or acute leukemia of ambiguous lineage (ALAL) that has come …
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New immunotherapy combo shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis is an open-label, multi-center study of Phase Ib/II study to assess the efficacy and safety of Envafolimab combinded with Lenvatinib in the treatment of subjects with advanced solid tumors. The primary hypothesis of this study is that subjects will have a better objective re…
Phase: PHASE1, PHASE2 • Sponsor: 3D Medicines (Sichuan) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Gold nanocrystals aim to slow ALS in new trial
Disease control OngoingThis is an optional open-label extension to participants that have completed the clinical trial CNMAu8.205.
Phase: PHASE2 • Sponsor: Clene Nanomedicine • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Talking therapy boosts HIV control in abused women
Disease control CompletedThis study will evaluate the impact of the Common Elements Treatment Approach (CETA), an evidence-based intervention comprised of cognitive-behavioral therapy elements, at improving HIV treatment outcomes among women with HIV who have experienced intimate partner violence (IPV) a…
Phase: NA • Sponsor: Boston University • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Immunotherapy boost before surgery shows promise for rare urinary tract cancer
Disease control Recruiting nowThis phase II/III trial compares the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery in treating patients with upper urinary tract cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack t…
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New cell therapy TAK-007 tested in lymphoma patients who have run out of options
Disease control OngoingThis study has 2 parts. The main aim of Part 1 is to check for side effects from TAK-007 in adults with relapsed or refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL), The main aim of Part 2 is to learn whether lymphoma disease responds to treatment with TAK-007 in adults with …
Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Hope for rare kidney patients: new drug shows promise in phase 3 trial
Disease control CompletedThis is a Phase 3 study to assess the efficacy and safety of twice-weekly subcutaneous (SC) doses of pegcetacoplan compared to placebo in patients with C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN) on the basis of a reduction in prot…
Phase: PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Could an antibiotic boost chemo for breast cancer?
Disease control CompletedThe primary objective of this study is to compare disease-free survival (DFS) of patients with operable breast cancer randomised to treatment with standard adjuvant chemotherapy plus moxifloxacin or placebo.
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New nasal vaccine could stop whooping cough in its tracks
⭐️ VACCINE ⭐️ CompletedThis study evaluates the safety and immunogenicity of the BPZE1 live, attenuated pertussis vaccine, intended to prevent nasopharyngeal colonization and pertussis disease, and compares BPZE1 vaccine vs Boostrix vaccine vs both BPZE1 and Boostrix vaccines. This is a multi-center, r…
Phase: PHASE2 • Sponsor: ILiAD Biotechnologies • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 07:56 UTC